Hepatotoxicity in HIV infected patients with HBsAg and Anti-HCV antibodies receiving Antiretroviral therapy containing protease Inhibitors
Mani Goel, VS Chopra, Roma Goyal, Anil Kumar, Shubhanshu Gupta
Background: Twenty-one antiretroviral drugs have been accepted by the U.S. Food and Drug Administration (FDA) for the treatment of HIV. This study was done to study the protease inhibitors. Objectives: to determine the correlation of Hepatotoxicity in HIV patients with HBsAg and anti-HCV antibodies. Methods: A Hospital based cross sectional study among 280 HIV seropositive patient who reported to ART centre for treatment at LLRM Medical College & Hospital, Meerut. The patients reconfirmed to be HIV positive underwent liver function test (LFT), hepatitis test and CD4 cell count before initiation of therapy. Epi info 7 was used for analysis. Results: ALT levels which were normal in 258 (92%) patients and raised in 22 (8%) patients before initiation of therapy and were found to be normal in 112 (40%) patients and raised in 168 (60%) patients after 9 months of initiation of therapy and both before and after initiation of therapy were found to be statistically highly significant. Conclusion: Hepatotoxicity developed in HBs Ag and HCV coinfected patients was significantly higher as compared to patients without coinfection, showed that viral hepatitis coinfections are self-determining risk factors for hepatotoxicity.
Mani Goel, VS Chopra, Roma Goyal, Anil Kumar, Shubhanshu Gupta. Hepatotoxicity in HIV infected patients with HBsAg and Anti-HCV antibodies receiving Antiretroviral therapy containing protease Inhibitors. International Journal of Medicine Research, Volume 4, Issue 2, 2019, Pages 01-04